Released Nov 2, 2021, before the open
10-Q filed Nov 2, 2021, 33 days after period end · 0000917520-21-000049
Q3 2021 · 10-Q
Revenue$386.86M$386.86M +4.5% vs Q3 2020−0.8% vs Q2 2021
Net Income$43.23M$43.23M +33.7% vs Q3 2020+23.3% vs Q2 2021
EPS Diluted$0.51$0.51 +34.2% vs Q3 2020+24.4% vs Q2 2021
Operating Income$56,439,000−1.9%
Operating Cash Flowderived$82,779,000+18.9%
Free Cash Flowderived$75,493,000+20.0%
Margins · derived
Operating margin14.6%−1.0 pt vs Q3 2020
Net margin11.2%+2.4 pt vs Q3 2020
What the release said
The release
Same quarter
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Revenue | $386.86M | $370.23M | $379.10M | $365.85M |
| Net Income | $43.23M | $32.34M | -$27.61M | $13.30M |
| EPS Diluted | $0.51 | $0.38 | -$0.32 | $0.15 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR